Skip to content

Study · Systematic review · 2023

3 results

Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.

Li Y, Lei R, Lei H, Xiong Q, Xie F, Yao C, Feng P

European journal of gastroenterology & hepatology1 Jan 2023Cited by 9 (Europe PMC)

PMID36468565 (opens in a new tab)DOI10.1097/meg.0000000000002471 (opens in a new tab)PepBankPUB-36468565
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a network meta-analysis of NAFLD fibrosis trials, liraglutide ranked highest for the risk of constipation.

    In plain wordsIn a network meta-analysis of fatty liver drugs, liraglutide ranked as the drug with the highest risk of constipation.

    Peptide
    Liraglutide
    Outcome
    IncreaseConstipation (SUCRA ranking)
    Study

    n: not reported in source

    Comparator
    Other pharmacologic agents in the network
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    92.9 SUCRA
    constipation

    Source sentences

    Summary
    SUCRA analysis suggested that the lanifibranor group had the highest risk of diarrhea (SUCRA, 94), whereas the liraglutide group had the highest risk of constipation (SUCRA, 92.9).
    1 context sentence
    Summary · context
    A total of 26 RCTs with 19 interventions met the inclusion criteria.
  2. 02HumanSystematic reviewSafety outcome

    In a network meta-analysis of NAFLD fibrosis trials, semaglutide ranked highest for the incidence of nausea.

    In plain wordsIn a network meta-analysis of fatty liver drugs, semaglutide ranked as the drug with the highest rate of nausea.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea (SUCRA ranking)
    Study

    n: not reported in source

    Comparator
    Other pharmacologic agents in the network
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    81.2 SUCRA
    nausea

    Source sentences

    Summary
    The semaglutide group showed the highest incidence of nausea (SUCRA, 81.2) and abdominal pain (SUCRA, 90.5), respectively.
    1 context sentence
    Summary · context
    A total of 26 RCTs with 19 interventions met the inclusion criteria.
  3. 03HumanSystematic reviewSafety outcome

    In a network meta-analysis of NAFLD fibrosis trials, semaglutide ranked highest for the incidence of abdominal pain.

    In plain wordsIn a network meta-analysis of fatty liver drugs, semaglutide ranked as the drug with the highest rate of abdominal pain.

    Peptide
    Semaglutide
    Outcome
    IncreaseAbdominal pain (SUCRA ranking)
    Study

    n: not reported in source

    Comparator
    Other pharmacologic agents in the network
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    90.5 SUCRA
    abdominal pain

    Source sentences

    Summary
    The semaglutide group showed the highest incidence of nausea (SUCRA, 81.2) and abdominal pain (SUCRA, 90.5), respectively.
    1 context sentence
    Summary · context
    A total of 26 RCTs with 19 interventions met the inclusion criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.